Outsourcing-Pharma discusses the EZcohort® program launched at Taconic Biosciences:
"According to the company, the EZcohort® program was developed in response to "a need for speed and predictability in drug discovery."
Dr. Michael Seiler, portfolio director, Commercial Genetically Engineered Models, Taconic Biosciences, told us the company has "innovated in the transactional space."
"Instead of requiring materials transfer agreements, as many repository vendors do, we sell these under a label license and we make it very clear that the terms and conditions are to use, breed, and crossbreed these valuable genetically engineered models," he said." Read the complete article at: Outsourcing-Pharma.com
"According to the company, the EZcohort® program was developed in response to "a need for speed and predictability in drug discovery." Dr. Michael Seiler, portfolio director, Commercial Genetically Engineered Models, Taconic Biosciences, told us the company has "innovated in the transactional space."
"Instead of requiring materials transfer agreements, as many repository vendors do, we sell these under a label license and we make it very clear that the terms and conditions are to use, breed, and crossbreed these valuable genetically engineered models," he said."